Home » Stocks » ALT

Altimmune, Inc. (ALT)

Stock Price: $12.74 USD -0.11 (-0.86%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 479.24M
Revenue (ttm) 8.19M
Net Income (ttm) -49.04M
Shares Out 25.64M
EPS (ttm) -1.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $12.74
Previous Close $12.85
Change ($) -0.11
Change (%) -0.86%
Day's Open 12.81
Day's Range 12.41 - 13.44
Day's Volume 698,707
52-Week Range 4.27 - 35.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial result...

2 days ago - GlobeNewsWire

Altimmune Inc (NASDAQ: ALT) has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-CoV-2 challenge model of infection. The resul...

3 days ago - Benzinga

Data Show No Detectable Levels of Infectious Virus in Lungs of Vaccinated Mice Following Challenge with SARS-CoV-2

3 days ago - GlobeNewsWire

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

Alternus Energy Group PLC (NOTC:ALT) named industry veteran Gary Swan as its chief technical officer, as the fast-growing independent power producer expands its footprint across Europe.  “Swan will join...

3 weeks ago - Proactive Investors

Alternus Energy Group PLC (NOTC:ALT), the fast-growing pan-European independent power producer, announced the recent issuance of €9 million convertible notes lead by AVG Group Sarl, a Luxembourg-based a...

1 month ago - Proactive Investors

10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX)  presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therape...

Other stocks mentioned: AUIAF, AURQF, AUSAF, BABYF, CAAOF, CRTPF, GNPX ...
1 month ago - Proactive Investors

The short answer: It depends.

1 month ago - The Motley Fool

Altimmune Inc (NASDAQ: ALT) has reported data from Phase 1b trial evaluating its NasoShield intranasal anthrax vaccine candidate. The 1b trial evaluated the safety and immunogenicity of one and two-dose...

1 month ago - Benzinga

GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine...

1 month ago - GlobeNewsWire

Alternus Energy Group PLC (NOTC:ALT), the fast-growing pan-European independent power producer, has announced the completion of the acquisition of two additional solar parks in Romania from Renesola Pow...

1 month ago - Proactive Investors

Metered Multidose Device Allows for Convenient and Cost-effective Vaccination Metered Multidose Device Allows for Convenient and Cost-effective Vaccination

1 month ago - GlobeNewsWire

If you're thinking of investing in this spectacular coronavirus growth stock, now may be too late.

1 month ago - The Motley Fool

Altimmune Inc. (NASDAQ: ALT) is making headway in the fight against COVID-19 after the firm announced additional preclinical data in regards to its single-dose intranasal vaccine candidate, AdCOVID.

1 month ago - 24/7 Wall Street

Altimmune Inc (NASDAQ: ALT) has reported additional preclinical data for COVID-19 vaccine candidate, AdCOVID. The data showed that a single intranasal dose of AdCOVID provided 100% protection against th...

1 month ago - Benzinga

Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the sto...

Other stocks mentioned: CFRX, EVOK, NVAX
2 months ago - Benzinga

Altimmune Inc (NASDAQ: ALT) has expanded its previously-announced manufacturing collaboration with Lonza Group (OTCMKT: LZAGY) for AdCOVID, its single-dose intranasal COVID-19 vaccine candidate. Under t...

2 months ago - Benzinga

Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune's COVID-19 Vaccine Candidate at its Houston Facility Lonza to Commission a Dedicated Suite for Clinical and Commerci...

2 months ago - GlobeNewsWire

Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing internatio...

2 months ago - Proactive Investors

Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing internatio...

2 months ago - Proactive Investors

GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a...

2 months ago - GlobeNewsWire

Green energy is finally going mainstream, providing predictable long-term returns, with wind and solar power part of the investment megatrend and in this Alternus Energy Group PLC (NOTC:ALT) is particul...

2 months ago - Proactive Investors

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 79.76% and 38.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Nasal spray may offer room temperature distribution that could reduce logistical  challenges for healthcare systems and providers

2 months ago - GlobeNewsWire

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results o...

2 months ago - GlobeNewsWire

The company's COVID-19 program is moving ahead.

2 months ago - The Motley Fool

Altimmune Inc (NASDAQ: ALT) shares are advancing following an update on its coronavirus vaccine program. What Happened: Maryland-based Altimmune said the FDA has cleared its investigational new drug app...

2 months ago - Benzinga

Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week Enrollment in Phase 1 clinical trial of single-dose, needle-free, ...

2 months ago - GlobeNewsWire

No kidding around ... here's how they truly can.

Other stocks mentioned: JUSHF, VXRT
3 months ago - The Motley Fool

New York, New York--(Newsfile Corp. - January 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such investors are ad...

4 months ago - Newsfile Corp

Transport and storage of their potential vaccines would be a piece of cake.

Other stocks mentioned: VXRT
4 months ago - The Motley Fool

This biotech just might have what it takes.

4 months ago - The Motley Fool

They're risky but could deliver huge returns in the new year.

Other stocks mentioned: NVAX, VXRT
4 months ago - The Motley Fool

Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.

4 months ago - Zacks Investment Research

Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimmune...

Other stocks mentioned: BCDA, INCY
4 months ago - Benzinga

GAITHERSBURG, Md., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its multinationa...

4 months ago - GlobeNewsWire

It's down, but not out.

4 months ago - The Motley Fool

Biotechvalley Insights is upgrading ALT's rating to "Very Bullish" from a "Bullish" rating with a 12 month TP of US$52. Altimmune's (ALT) valuation is at a discount after the recent sell-off, and the fu...

4 months ago - Seeking Alpha

Altimmune Inc. (NASDAQ: ALT) shares dropped on Thursday after the company announced that it had received an update from the U.S.

4 months ago - 24/7 Wall Street

Altimmune, a clinical-stage biopharmaceutical company, fell as much as 10% on Thursday after the FDA issued a clinical hold on the company's COVID-19 vaccine candidate. AdCOVID is a single-dose intranas...

4 months ago - Business Insider

GAITHERSBURG, Md., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issue...

4 months ago - GlobeNewsWire

Investors are excited about an analyst's bullish opinion about the biotech stock.

4 months ago - The Motley Fool

GAITHERSBURG, Md., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer of Altimmune ...

5 months ago - GlobeNewsWire

Share price has recently stumbled due to results of the leading vaccines. Vaccine development timeline is way behind the leading vaccines.

5 months ago - Seeking Alpha

Altimmune (ALT) files a regulatory application to begin a phase I study in the United States on AdCOVID, its intranasal COVID-19 vaccine candidate. Stock rises.

5 months ago - Zacks Investment Research

Simple, single-dose nasal spray offers greater ease and comfort of administration ;  positioning AdCOVID as a differentiated vaccine candidate for adults and children

5 months ago - GlobeNewsWire

GAITHERSBURG, Md., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for live...

5 months ago - GlobeNewsWire

Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Altimmune Inc. (NASDAQ: ALT) stepped forward on Tuesday with its vaccine candidate for COVID-19.

6 months ago - 24/7 Wall Street

AdCOVID , a Single-dose Intranasal Vaccine for COVID-19 is Designed to Generate a Broad Immune Response Against COVID-19 with the Unique Ability to Promote Nasal Mucosal Immunity

6 months ago - GlobeNewsWire

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that i... [Read more...]

Industry
Biotechnology
CEO
Vipin Garg
Employees
43
Stock Exchange
NASDAQ
Ticker Symbol
ALT
Full Company Profile

Financial Performance

In 2020, Altimmune's revenue was $8.19 million, an increase of 41.09% compared to the previous year's $5.80 million. Losses were -$49.04 million, 139.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Altimmune stock is "Strong Buy." The 12-month stock price forecast is 41.83, which is an increase of 228.34% from the latest price.

Price Target
$41.83
(228.34% upside)
Analyst Consensus: Strong Buy